MedDataX Logo

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

NCT ID: NCT01986491

Last Updated: 2013-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the pharmacokinetics (what a medication does to the body), dose-proportionality, safety and tolerability of JNJ 39393406 following single dose oral administration of two solid oral formulations in Part 1; based on the profile in Part 1, one of the formulations assessed will be selected to investigate the pharmacokinetics in fasting condition in Part 2 and after repeated dosing in Part 3.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label (all people know the identity of the intervention) and single center study that will be conducted in 3 parts (Part 1, Part 2, and Part 3). The study consists of 3 phases including, the screening phase, treatment phase, and the follow-up phase. Part 1 is a four-way cross-over (method used to switch participants from one treatment arm to another in a clinical study) study to compare the pharmacokinetics, dose-proportionality, safety and tolerability of JNJ 39393406 following single dose oral administration of two solid oral formulations (X and Y). Approximately 12 participants will be enrolled in Part 1. Part 2 is two-way cross-over study in a separate group of participants to assess pharmacokinetics in fasting condition and the relative bioavailability (the extent to which a medication or other substance becomes available to the body) of the selected solid formulation from Part 1 compared with a solution formulation. Approximately 8 participants will be enrolled in Part 2. In Part 3, the single and repeated dose pharmacokinetics after administration of the selected formulation from Part 1 will be assessed for 7 consecutive days. The same participants will participate in Parts 2 and 3 of the study. Safety will be evaluated by the assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, physical examination, and neurological examination. The duration of participation in the study for an individual participant will be approximately 8 weeks (including screening and follow up visit).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Healthy JNJ-39393406 Relative Bioavailability Solid Formulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1; Period 1

Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 120 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 120 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Part 1; Period 2

Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 120 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 120 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Part 1; Period 3

Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 120 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 120 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Part 1; Period 4

Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 120 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 120 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Part 2; Period 1

Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 120 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 120 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 30 mg solution

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).

Part 2; Period 2

Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 120 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 120 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

JNJ 39393406 30 mg solution

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).

Part 3

Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.

Group Type EXPERIMENTAL

JNJ 39393406 30 mg solid X

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

JNJ 39393406 30 mg solid Y

Intervention Type DRUG

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ 39393406 30 mg solid X

Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

Intervention Type DRUG

JNJ 39393406 30 mg solid Y

Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention Type DRUG

JNJ 39393406 120 mg solid X

Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention Type DRUG

JNJ 39393406 120 mg solid Y

Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention Type DRUG

JNJ 39393406 30 mg solution

Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male participants
* Body mass index (BMI) between 18 and 30 kg/m2 (BMI is calculated as weight \[kilogram\] divided by square of height \[meter\])
* Willing to adhere to the prohibitions and restrictions specified in the protocol
* Must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria

* Clinically significant abnormal values for clinical chemistry, hematology or urinalysis at screening or admission
* Clinically significant abnormal physical examination, neurological examination, vital signs or 12 lead electrocardiogram at screening
* Significant history of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematological disease, bronchospastic respiratory disease, dyspnea, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, infection, or any other illness that the investigator considers clinically significant
* Significant history of or current psychiatric or neurological illness
* Serology positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus antibodies at screening
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johnson & Johnson Pharmaceutical Research & Development Clinical Trial

Role: STUDY_DIRECTOR

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Antwerp, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

39393406EDI1003

Identifier Type: OTHER

Identifier Source: secondary_id

CR016264

Identifier Type: -

Identifier Source: org_study_id